AR011080A1 - Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento - Google Patents

Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento

Info

Publication number
AR011080A1
AR011080A1 ARP980100224A ARP980100224A AR011080A1 AR 011080 A1 AR011080 A1 AR 011080A1 AR P980100224 A ARP980100224 A AR P980100224A AR P980100224 A ARP980100224 A AR P980100224A AR 011080 A1 AR011080 A1 AR 011080A1
Authority
AR
Argentina
Prior art keywords
composition
manufacture
preparation
dry powder
medicinal product
Prior art date
Application number
ARP980100224A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011080(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR011080A1 publication Critical patent/AR011080A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Abstract

Composicion en polvo seco que comprende una o más sustancias farmacéuticamente activas y una sustancia portadora, todas ellas tienenla forma finamente dividida, donde la formulacion tiene una densidad global vertida deentre 0,28 y 0,38 g/ml, util para el tratamiento detrastornos respiratorios, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento. Las sustancias farmacéuticasactivas son seleccionadas preferentementeentre budesonide y formoterol. Un proceso para preparar una composicion de acuerdo con la reivindicacion 1, quecomprende: (a) micronisar una o más sustancias farmacéuticamente activas potentes y una sustancia portadora; (b) opcionalmenteacondi cionar el producto;y (c) formar esferas hasta obtener la densidad global deseada.
ARP980100224A 1997-01-20 1998-01-19 Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento AR011080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9700135A SE9700135D0 (sv) 1997-01-20 1997-01-20 New formulation

Publications (1)

Publication Number Publication Date
AR011080A1 true AR011080A1 (es) 2000-08-02

Family

ID=20405455

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100224A AR011080A1 (es) 1997-01-20 1998-01-19 Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento

Country Status (35)

Country Link
US (2) US6030604A (es)
EP (1) EP1007017B2 (es)
JP (1) JP2010059181A (es)
KR (1) KR100528416B1 (es)
CN (1) CN1271993C (es)
AR (1) AR011080A1 (es)
AT (1) ATE288260T1 (es)
AU (1) AU731192B2 (es)
BR (1) BR9811249A (es)
CA (1) CA2277913C (es)
CZ (1) CZ296301B6 (es)
DE (1) DE69828886T3 (es)
DK (1) DK1007017T4 (es)
EE (1) EE03951B1 (es)
ES (1) ES2235311T5 (es)
HK (1) HK1025515A1 (es)
HU (1) HU228622B1 (es)
ID (1) ID21865A (es)
IL (1) IL130838A (es)
IS (1) IS2788B (es)
MY (1) MY132999A (es)
NO (1) NO327426B1 (es)
NZ (1) NZ336594A (es)
PL (1) PL192115B1 (es)
PT (1) PT1007017E (es)
RU (1) RU2194497C2 (es)
SA (1) SA98180818B1 (es)
SE (1) SE9700135D0 (es)
SI (1) SI1007017T2 (es)
SK (1) SK283950B6 (es)
TR (1) TR199901690T2 (es)
TW (1) TW557217B (es)
UA (1) UA57764C2 (es)
WO (1) WO1998031352A1 (es)
ZA (1) ZA9878B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
JP2002532405A (ja) * 1998-12-11 2002-10-02 ファルマヘミー ベー．フェー． オピオイド吸入製剤
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US6623760B1 (en) * 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
TWI277425B (en) * 1999-04-13 2007-04-01 Lilly Co Eli Pulmonary administration of dry powder formulations for treating infertility
CA2273585A1 (en) 1999-05-28 2000-11-28 Canpolar East Inc. Sensors for detecting changes in temperature, ph, chemical conditions, biological conditions, radiation, electrical field and pressure
DE19962926A1 (de) * 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Co-Mahlung von Stoffen und Lactose mittels Strahlmühlen
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
WO2001078735A1 (en) * 2000-04-13 2001-10-25 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
WO2002011711A2 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
WO2002062317A2 (en) * 2001-02-06 2002-08-15 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
WO2003094967A2 (en) * 2002-05-07 2003-11-20 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
NZ538965A (en) * 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004052374A1 (en) * 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
CA2525943A1 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Salmeterol and ciclesonide combination
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
DK1699434T3 (da) 2003-09-02 2011-05-30 Norton Healthcare Ltd Fremgangsmåde til fremstilling af et lægemiddel
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
GEP20094781B (en) * 2004-01-22 2009-09-25 Pfizer Sulfonamide derivatives for the treatment of diseases
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
PE20060159A1 (es) * 2004-03-24 2006-04-04 Chiesi Farma Spa Monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-{[(1r)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2-(1h)-quinolinona en forma cristalina y el proceso para su preparacion
US20070134165A1 (en) * 2004-04-20 2007-06-14 Altana Pharma Ag Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
BRPI0509348A (pt) 2004-04-21 2007-09-11 Innovata Biomed Ltd inalador
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
JP2008524195A (ja) * 2004-12-17 2008-07-10 シプラ・リミテッド 医薬化合物および組成物
JP5156397B2 (ja) * 2005-02-10 2013-03-06 グラクソ グループ リミテッド 予備分級技術を用いて乳糖を製造する方法及びその乳糖から形成させた医薬製剤
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
AU2006269961B2 (en) * 2005-07-15 2012-07-19 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
EP1904219A4 (en) * 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US8604080B2 (en) 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EP2435023B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta 2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
BR112013008974A2 (pt) 2010-10-12 2023-12-19 Cipla Ltd Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica
WO2012074856A2 (en) 2010-11-24 2012-06-07 Lithera, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2013153349A2 (en) 2012-04-11 2013-10-17 Cipla Limited Pharmaceutical composition
RU2510267C2 (ru) * 2012-06-15 2014-03-27 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
AU2014228414B2 (en) 2013-03-15 2018-09-13 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP2821062A1 (en) 2013-07-01 2015-01-07 Arven Ilac Sanayi Ve Ticaret A.S. Novel dry powder inhaler formulations
AU2018318123A1 (en) 2017-08-15 2020-03-19 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
MX2021014343A (es) * 2019-05-24 2022-01-06 Glenmark Pharmaceutical Ltd Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4161516A (en) † 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
ATE23272T1 (de) * 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB8825541D0 (en) † 1988-11-01 1988-12-07 Fisons Plc Formulation
EP0705614B1 (en) * 1989-04-28 2002-09-25 Riker Laboratories, Inc. Dry powder inhalation device
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
DK0441740T3 (da) † 1990-01-29 1993-11-08 Ciba Geigy Ag Fremgangsmåde og apparat til dosering af et firkornet pulver
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
DE69208660T2 (de) * 1991-06-10 1996-07-11 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
PT613371E (pt) * 1991-12-18 2002-07-31 Astrazeneca Ab Nova combinacao de formoterol e budesonido
US5355872B1 (en) * 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
ES2177544T3 (es) † 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
EP0665010B1 (en) * 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
EP0714279B1 (en) * 1993-08-18 1998-12-30 Unilever Plc Shaving composition
ATE209903T1 (de) * 1993-10-01 2001-12-15 Astrazeneca Ab Verfahren i
IS1736B (is) * 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9404945D0 (en) † 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US5647347A (en) * 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation

Also Published As

Publication number Publication date
KR100528416B1 (ko) 2005-11-16
DK1007017T3 (da) 2005-05-02
CA2277913A1 (en) 1998-07-23
IS5108A (is) 1999-07-06
EP1007017A1 (en) 2000-06-14
TR199901690T2 (xx) 1999-09-21
CN1271993C (zh) 2006-08-30
SI1007017T1 (en) 2005-06-30
AU5785998A (en) 1998-08-07
TW557217B (en) 2003-10-11
ATE288260T1 (de) 2005-02-15
HK1025515A1 (en) 2000-11-17
JP2001508793A (ja) 2001-07-03
EE9900295A (et) 2000-02-15
ZA9878B (en) 1998-07-20
PL334527A1 (en) 2000-02-28
NZ336594A (en) 2001-01-26
CN1243436A (zh) 2000-02-02
EP1007017B1 (en) 2005-02-02
CZ296301B6 (cs) 2006-02-15
DK1007017T4 (da) 2011-02-28
PT1007017E (pt) 2005-05-31
DE69828886T2 (de) 2006-04-06
SE9700135D0 (sv) 1997-01-20
UA57764C2 (uk) 2003-07-15
US6030604A (en) 2000-02-29
SK95999A3 (en) 2000-01-18
EE03951B1 (et) 2003-02-17
DE69828886D1 (de) 2005-03-10
NO993539D0 (no) 1999-07-19
IL130838A0 (en) 2001-01-28
CA2277913C (en) 2007-03-06
SI1007017T2 (sl) 2011-03-31
ES2235311T5 (es) 2011-03-31
IL130838A (en) 2005-07-25
JP4512204B2 (ja) 2010-07-28
NO327426B1 (no) 2009-06-29
ID21865A (id) 1999-08-05
CZ255799A3 (cs) 1999-10-13
EP1007017B2 (en) 2010-12-08
SK283950B6 (sk) 2004-05-04
JP2010059181A (ja) 2010-03-18
MY132999A (en) 2007-10-31
KR20000070188A (ko) 2000-11-25
HU228622B1 (en) 2013-04-29
WO1998031352A1 (en) 1998-07-23
US6287540B1 (en) 2001-09-11
BR9811249A (pt) 2000-09-05
IS2788B (is) 2012-06-15
SA98180818B1 (ar) 2006-03-25
PL192115B1 (pl) 2006-08-31
NO993539L (no) 1999-09-20
AU731192B2 (en) 2001-03-29
DE69828886T3 (de) 2011-06-01
HUP0000714A2 (hu) 2000-08-28
RU2194497C2 (ru) 2002-12-20
ES2235311T3 (es) 2005-07-01
HUP0000714A3 (en) 2000-10-30
ES2235311T8 (es) 2011-05-13

Similar Documents

Publication Publication Date Title
AR011080A1 (es) Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
AR002009A1 (es) Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
CL2004001191A1 (es) Compuestos derivados de esteroides 17 alpha-fluoroalquilados, con actividad antigestagena; composicion farmaceutica; combinacion farmaceutica; y uso del compuesto en la preparacion de un medicamento antiestrogenico, para el tratamiento de dismenorrea
AR015524A1 (es) FORMULACIoN ESTABLE DE SOLUCIoN DE OXIPLATINO, SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO, PROCESO PARA SU PREPARACIoN, PRODUCTO FARMACÉUTICO QUE LA CONTIENE Y UN MÉTODO PARA ESTABILIZAR UNA SOLUCIoN DE OXALIPLATINO.
ATE368450T1 (de) Pharmazeutische aerosolzubereitung, die hfa227 und hfa 134a enthält
DE59409568D1 (de) Wirkstoffe und gas enthaltende mikropartikel
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
BR0012351A (pt) Pós consistindo de partìculas com uma superfìcie perfeitamente macia, para uso como veìculos para a preparação de misturas de inalação com medicamentos micronizados e o método para sua preparação
HUP0004821A2 (hu) Lágy pellet alakjában lévő gyógyszerkészítmény és előállítása
HUP0102337A2 (hu) Eljárás gyulladásgátló, különösen fertőtlenítő hatású és/vagy sebgyógyulást elősegítő szerek felső légutakba és/vagy fülbe történő beadására szolgáló készítmények előállítására
AR009231A1 (es) Formulaciones en aerosol de formoterol.
CA2302276A1 (en) Methods of treating capsules and dry, powdered pharmaceutical formulations
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
AR015820A1 (es) Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
HUP0000843A2 (hu) Formoterolt tartalmazó, 028-0,38 g/ml szórósűrűségű, új inhalációs gyógyszerforma
RU2001117835A (ru) Способ размола для получения тонкоизмельченных медицинских субстанций
SE9700133D0 (sv) New formulation
HUP0300334A2 (hu) Gyógyászati készítmények és eljárások azok elżállítására
BR9913782A (pt) Processo de preparação de uma formualação galênica que compreende fenofibrato como princìpio ativo, formulação galênica, medicamento e utilizações de um meio lìquido e de partìculas de fenofibrato
AR012480A1 (es) Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona
HUP0003207A2 (hu) Tokoferollal stabilizált proliposzóma porok inhalációs célra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
SE8601457D0 (sv) Compositions of liposomes and b?712-receptor active substances for inhalation
HUP0000755A2 (hu) Terbutalin-szulfátot tartalmazó, 0,28-0,38 g/ml szórósűrűségű, új inhalációs gyógyszerforma, eljárás előállítására és alkalmazása

Legal Events

Date Code Title Description
FC Refusal